Patents by Inventor Esther Bachar-Lustig
Esther Bachar-Lustig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230398214Abstract: Methods of generating an isolated population of non-graft versus host disease (GVHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, are disclosed. Cells generated by the methods, pharmaceutical compositions and methods of treatment are also disclosed.Type: ApplicationFiled: August 6, 2020Publication date: December 14, 2023Applicants: Yeda Research and Development Co. Ltd., Board of Regents, The University of Texas SystemInventors: Yair REISNER, Esther BACHAR-LUSTIG, Assaf LASK, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Rakefet SIDLIK MUSKATEL
-
Publication number: 20230383254Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.Type: ApplicationFiled: August 10, 2023Publication date: November 30, 2023Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
-
Publication number: 20230321235Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.Type: ApplicationFiled: August 11, 2021Publication date: October 12, 2023Applicants: Yeda Research and Development Co. Ltd., Ichilov Tech Ltd.Inventors: Yair REISNER, Anat GLOBERSON LEVIN, Esther BACHAR-LUSTIG, Assaf LASK, Bar NATHANSOHN-LEVI, Tova WAKS, Galit HORN, Zelig ESHHAR
-
Patent number: 11773372Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.Type: GrantFiled: March 25, 2021Date of Patent: October 3, 2023Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Noga Or-Geva, Rotem Gidron Budovsky, Esther Bachar-Lustig, Assaf Lask, Sivan Kagan
-
Publication number: 20230256028Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.Type: ApplicationFiled: April 21, 2023Publication date: August 17, 2023Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Carmit HILLEL-KARNIEL, Chava ROSEN, Esther BACHAR-LUSTIG, Elias SHEZEN
-
Publication number: 20230039904Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.Type: ApplicationFiled: October 2, 2022Publication date: February 9, 2023Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Esther BACHAR-LUSTIG
-
Publication number: 20230024587Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.Type: ApplicationFiled: May 3, 2022Publication date: January 26, 2023Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Yaki EIDELSTEIN, Eran OPHIR, Assaf LASK, Ran AFIK, Noga OR-GEVA, Esther BACHAR-LUSTIG
-
Patent number: 11555178Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.Type: GrantFiled: January 18, 2018Date of Patent: January 17, 2023Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig, Shlomit Reich-Zeliger
-
Patent number: 11504399Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoietic cells are obtained by separating the T cells from the immature hematopoietic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.Type: GrantFiled: August 13, 2019Date of Patent: November 22, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig
-
Patent number: 11497776Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.Type: GrantFiled: July 11, 2019Date of Patent: November 15, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig
-
Patent number: 11324777Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.Type: GrantFiled: November 29, 2017Date of Patent: May 10, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Yaki Eidelstein, Eran Ophir, Assaf Lask, Ran Afik, Noga Or-Geva, Esther Bachar-Lustig
-
Publication number: 20210214687Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.Type: ApplicationFiled: March 25, 2021Publication date: July 15, 2021Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
-
Patent number: 10961504Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.Type: GrantFiled: June 27, 2017Date of Patent: March 30, 2021Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Noga Or-Geva, Rotem Gidron Budovsky, Esther Bachar-Lustig, Assaf Lask, Sivan Kagan
-
Patent number: 10751368Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of tolerance inducing anti-third party cytotoxic T-lymphocytes (CTLs), wherein the tolerance inducing anti-third party CTLs are generated by directing T-lymphocytes of a donor against a third party antigen or antigens, the tolerance inducing anti-third party CTLs being substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, and wherein the tolerance inducing anti-third party CTLs do not comprise cells having a central memory T-lymphocyte (Tcm) phenotype, wherein the cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.Type: GrantFiled: January 18, 2018Date of Patent: August 25, 2020Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig, Shlomit Reich-Zeliger
-
Publication number: 20190358269Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The methods comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.Type: ApplicationFiled: August 13, 2019Publication date: November 28, 2019Applicant: Yeda Research And Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig
-
Publication number: 20190338247Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.Type: ApplicationFiled: January 18, 2018Publication date: November 7, 2019Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Esther BACHAR-LUSTIG, Shlomit REICH-ZELIGER
-
Publication number: 20190328793Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.Type: ApplicationFiled: July 11, 2019Publication date: October 31, 2019Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Esther BACHAR-LUSTIG
-
Publication number: 20190316087Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.Type: ApplicationFiled: June 27, 2017Publication date: October 17, 2019Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
-
Patent number: 10434121Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.Type: GrantFiled: December 20, 2012Date of Patent: October 8, 2019Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig
-
Patent number: 10369172Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.Type: GrantFiled: December 20, 2012Date of Patent: August 6, 2019Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig